secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001193125-22-275406
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres reports Q3 2022 net loss $60M; SER-109 BLA accepted for Priority Review with PDUFA April 26, 2023
--------------------------------------------------------------------------------

- Net loss of $60.0M in Q3 2022 vs net income of $68.2M in Q3 2021; R&D expenses $43.1M.
- FDA accepted SER-109 BLA for Priority Review; PDUFA target action date April 26, 2023.
- ECOSPOR IV open-label study: 91.3% of patients achieved sustained clinical response at 8 weeks.
- Cash, cash equivalents and marketable securities $233.0M as of Sept 30, 2022.
- SER-155 cohort 1 enrollment complete; DSMB safety review by year end; initial data early 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312522275406/0001193125-22-275406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312522275406/d377816d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-275406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer